Dyadic Reports Q2 2025 Financial Results, Completes $5.3mln Equity Offering.

• Dyadic Applied BioSolutions reports Q2 2025 financial results • Completed $5.3 million equity offering • Rebranded from Dyadic to Dyadic Applied BioSolutions • Full website redesign for commercial execution • Achieved key milestones in life sciences and nutrition markets • Advanced multiple recombinant protein programs • Cash and equivalents at $7.3 million as of June 30, 2025

Dyadic Applied BioSolutions, formerly known as Dyadic International Inc., has released its financial results for the second quarter of 2025, highlighting significant progress in its transition from a research and development-focused company to a commercially driven biotechnology enterprise. The company reported total revenue of $967,000 for the three months ended June 30, 2025, marking an increase of $581,000 compared to the same period in 2024. For the six months ended June 30, 2025, total revenue was $1,360,000, an increase of $639,000 from the same period in 2024 [1].

The company's rebranding to Dyadic Applied BioSolutions and the full redesign of its corporate website reflect a strategic shift towards commercial execution and long-term value creation. These initiatives, along with a $5.3 million equity offering, have strengthened Dyadic's liquidity and positioned it to accelerate its commercial pipeline [2].

Dyadic has achieved key milestones in its life sciences and nutrition markets. The company is advancing multiple recombinant protein programs toward commercialization, including animal-free serum albumin, transferrin, and fibroblast growth factor. Additionally, Dyadic's DNase-1 enzyme, designed for use in molecular diagnostics and biopharmaceutical applications, is progressing toward commercial availability [2].

The company's financial results also reflect enhanced operational efficiency and cost management. Dyadic reported a loss from operations of $1,729,000 for the three months ended June 30, 2025, a decrease from $2,043,000 for the same period in 2024. The net loss for the three months ended June 30, 2025, was $1,794,000, down from $2,045,000 in the same period in 2024 [1].

Dyadic's cash and equivalents stood at $7.3 million as of June 30, 2025, with an additional $5.3 million of net proceeds from the equity offering on August 1, 2025 [2].

Dyadic Applied BioSolutions will host an earnings call at 5:00 pm ET on August 13, 2025, to discuss these results further. The company's strategic focus on scalable, non-animal protein production and its proprietary gene expression platforms position it to disrupt the cost, speed, and scalability of protein production across various markets.

References:
[1] https://www.tradingview.com/news/tradingview:e77a3d25d03c3:0-dyadic-international-inc-sec-10-q-report/
[2] https://www.globenewswire.com/news-release/2025/08/13/3132946/0/en/Dyadic-Reports-Second-Quarter-2025-Financial-Results-and-Highlights-of-Recent-Company-Progress.html